Agonist-induced activation of PPARγ has been demonstrated to increase insulin sensitivity [25, 26] and thiazolidinediones (TZD) are used clinically to reduce insulin resistance and hyperglycemia in patients with type 2 diabetes, although these drugs are also associated with weight gain [27–31]. Here, PPARG is linked to type 2 diabetes mellitus.